Learn how genetics, lifestyle, and medical innovations drive longevity. Discover science-backed strategies for a healthier, longer life.

Thank you for your dedicated career as a health care providing physician. I, like you, am closely connected to the health ...

Genflow Biosciences Provides Half Year Corporate Update on SIRT6 Programs, IP Progress and Strategic Partnerships LONDON, UK / ACCESS Newswire / June 17, 2025 / Genflow Biosciences Plc ...

Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results.

Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will ...

Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results.

Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results.